Last reviewed · How we verify
DC
DC is a dopamine agonist Biologic drug developed by Gary Archer Ph.D.. It is currently FDA-approved for Restless legs syndrome, Parkinson's disease. Also known as: DC vaccine, pp65 DC vaccine, Human CMV pp65-LAMP mRNA-pulsed autologous DCs, CMV pp65 DCs.
DC is a dopamine agonist that acts on dopamine receptors in the brain.
DC is a dopamine agonist that acts on dopamine receptors in the brain. Used for Restless legs syndrome, Parkinson's disease.
At a glance
| Generic name | DC |
|---|---|
| Also known as | DC vaccine, pp65 DC vaccine, Human CMV pp65-LAMP mRNA-pulsed autologous DCs, CMV pp65 DCs, Docetaxel Injection， Hengrui Medicine |
| Sponsor | Gary Archer Ph.D. |
| Drug class | dopamine agonist |
| Target | dopamine receptor |
| Modality | Biologic |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
DC works by mimicking the action of dopamine in the brain, which can help to improve symptoms of conditions such as restless legs syndrome and Parkinson's disease. This is achieved by binding to dopamine receptors, which can help to increase the levels of dopamine in the brain.
Approved indications
- Restless legs syndrome
- Parkinson's disease
Common side effects
- Nausea
- Dizziness
- Headache
Key clinical trials
- Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer (PHASE2)
- Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib (PHASE1)
- Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Newly Diagnosed Glioblastoma Multiforme (PHASE1, PHASE2)
- Family Genetics Health Education and Healthy Behaviors
- Traditional Chinese Medicine Ultrasonic Atomization Treatment for Dry Eye Disease (NA)
- Nucleoside Therapy in Patients With Telomere Biology Disorders (PHASE1)
- Performance of the Cardiac Microcurrent (C-MIC) System With a Less Invasively Placed Left Ventricular Lead (NA)
- Physiological Investigations of Movement Disorders (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DC CI brief — competitive landscape report
- DC updates RSS · CI watch RSS
- Gary Archer Ph.D. portfolio CI
Frequently asked questions about DC
What is DC?
How does DC work?
What is DC used for?
Who makes DC?
Is DC also known as anything else?
What drug class is DC in?
What development phase is DC in?
What are the side effects of DC?
What does DC target?
Related
- Drug class: All dopamine agonist drugs
- Target: All drugs targeting dopamine receptor
- Manufacturer: Gary Archer Ph.D. — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Restless legs syndrome
- Indication: Drugs for Parkinson's disease
- Also known as: DC vaccine, pp65 DC vaccine, Human CMV pp65-LAMP mRNA-pulsed autologous DCs, CMV pp65 DCs, Docetaxel Injection， Hengrui Medicine
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing